Latest News
Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
NEW YORK, June 02, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for the…
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
NEW YORK, April 20, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of a validation study aimed at significantly reducing the analysis time of its Intelligent Fingerprinting Drug Screening System. The study aims to improve the already…
Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified
NEW YORK, April 17, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabilities, verified the robustness of the Company’s existing security…